Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31
9/30/2026
Impact: -50
Healthcare
Goldman Sachs analyst Salveen Richter has maintained a Neutral rating on uniQure (NASDAQ: QURE) and has lowered the price target from $46 to $31. This adjustment reflects a change in the firm's outlook on the company's stock performance.
AI summary, not financial advice
Share: